This inventor holds 6 USPTO granted patents and 2 published patent applications. Top assignees: Mitsubishi Tanabe Pharma Corporation, K.K. Bcj-94. Active years: 2024-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024-2026
Title: Innovations of Yoshinobu Nakamaru
Introduction
Yoshinobu Nakamaru is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of oxidative stress diseases. With a total of three patents to his name, Nakamaru's work is recognized for its innovative approaches to drug administration.
Latest Patents
One of Nakamaru's latest patents is a pharmaceutical composition for the oral administration of edaravone. This method involves administering the composition to a subject in need, with specific time intervals after meal consumption. The patent outlines that the administration should occur at least 8 hours after a high-fat meal, 4 hours after a standard meal, or 2 hours after a light meal. This innovative approach aims to enhance the effectiveness of edaravone in treating oxidative stress diseases.
Career Highlights
Yoshinobu Nakamaru is currently associated with Mitsubishi Tanabe Pharma Corporation, where he continues to develop and refine his innovative ideas. His work has contributed to advancements in pharmaceutical treatments, particularly in the management of oxidative stress-related conditions.
Collaborations
Nakamaru has collaborated with notable colleagues such as Hidetoshi Shimizu and Yukiko Nishimura. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the pharmaceutical field.
Conclusion
Yoshinobu Nakamaru's contributions to pharmaceutical innovation, particularly through his patents on edaravone, highlight his commitment to improving treatment methods for oxidative stress diseases. His work continues to influence the pharmaceutical industry and offers hope for better therapeutic options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
